Cancer Prevention Supplements & Diet: The I-PREVENT + ROOT Protocol (2026)
Quick Answer: This framework merges OneDayMD's I-PREVENT Cancer Protocol with Dr. Paul Marik and Dr. Justus Hope's ROOT Protocol into a single five-layer system. Layer 1 is diet, metabolic health, and lifestyle — the original I-PREVENT foundation. Layers 2–3 are food-derived nutraceuticals (EGCG, curcumin, vitamin D3, omega-3, berberine, sulforaphane, vitamin C, magnesium, zinc, garlic, melatonin, and more), graded from strongest human-trial evidence to broader supporting data. Layer 4 is an optional Aged Garlic Extract upgrade. Layer 5 is Root 9 — the prescription drugs celecoxib, ivermectin, and mebendazole — which both authors scope strictly to people with confirmed hereditary cancer syndromes under specialist supervision, not general use. This is a prevention framework for healthy adults, not a cancer treatment protocol.
Medically reviewed and updated by the OneDayMD Editorial Team | Merged framework published July 12, 2026 | Synthesizes and supersedes two prior standalone articles (see Source Note below)
Table of Contents
- Introduction: Why We Merged Two Protocols Into One Framework
- Methodology & Evidence Grading (CEBM)
- The Five-Layer Cancer Prevention Framework
- Layer 1 — Foundation: Diet, Metabolic Health & Lifestyle
- Layer 2 — Core Nutraceuticals (Root 3)
- Layer 3 — Extended Nutraceuticals (Root 4–6 + I-PREVENT)
- Layer 4 — The Aged Garlic Extract (AGE) Upgrade
- Layer 5 — Hereditary-Risk Prescription Tier (Root 9)
- Dosing & Safety Reference Table
- The 2026 Evidence Debate: ASCO vs. the Repurposed-Drug Camp
- Which Layers Are Right for You?
- Key Takeaways
- Frequently Asked Questions
- Medical Disclaimer & Disclosures
Source note: This article merges and supersedes two OneDayMD Network publications: the original I-PREVENT Cancer Protocol (first published 2022, our own editorial framework), and Vitamin D to Ivermectin — A 2026 Cancer Prevention Framework, which itself synthesized two 2026 essays by Dr. Paul Marik, MD (with Dr. Justus Hope, MD) — "What the Public Is Not Told About Cancer Prevention" and "Preventing Cancer: The ROOT Protocols." The ROOT Protocol name, tier structure, and germline-risk framework originate with Drs. Marik and Hope; we credit that work throughout rather than presenting it as our own. OneDayMD has no financial relationship with Dr. Marik, Dr. Hope, or the Independent Medical Alliance (IMA).
1. Introduction: Why We Merged Two Protocols Into One Framework
Most people absorb a version of the cancer story that goes roughly like this: cancer is mostly genetic, mostly bad luck, and best addressed through early detection and ever-better drugs. That story isn't wrong, but it's incomplete — and the gap between "incomplete" and "actionable" is exactly where a prevention framework earns its keep.
.png)
We've published two separate resources that each covered part of that gap: I-PREVENT, our own diet-and-lifestyle-first framework running since 2022, and our synthesis of Dr. Paul Marik and Dr. Justus Hope's ROOT Protocol, a sequential nutraceutical escalation ladder. Readers kept asking the same question both articles were dancing around: how do these fit together, and in what order should I actually do things? This article answers that directly by combining both into one five-layer system, from diet on up to the prescription-drug tier reserved for hereditary risk.
The backdrop matters. The American Cancer Society projected over 2 million new U.S. cancer cases and more than 611,000 cancer deaths for 2024 alone, and a 2024 Lancet Public Health analysis found 17 cancer types becoming more common in younger generations — colorectal cancer now the leading cause of cancer death in men under 50. That shift has tracked closely with rising obesity, insulin resistance, sedentary living, and ultra-processed food consumption — a parallel that points toward a prevention model built around metabolic and inflammatory "terrain," not genetics alone.
A 2026 study in Nature Medicine estimated that at least 30 modifiable factors contribute to cancer risk, and that nearly 40% of cancer cases globally were preventable — three in ten cases in women, five in ten in men. Tobacco, high BMI, inactivity, and alcohol topped the list. That's the case for a layered, actionable framework rather than a single supplement or a single drug.
2. Methodology & Evidence Grading (CEBM)
Not all evidence is created equal, and this framework is explicit about the difference. We grade every claim using the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy, from strongest to weakest:
| CEBM Level | Evidence Type |
|---|---|
| Level 1 | Systematic reviews / meta-analyses of randomized controlled trials (RCTs) |
| Level 2 | Individual RCTs |
| Level 3 | Cohort studies, non-randomized controlled studies |
| Level 4 | Case series, case-control studies |
| Level 5 | Expert opinion, mechanistic/preclinical (cell-line, animal) data |
We analyzed a large body of primary literature — well over 1,000 references across both source protocols — while recognizing new research is continually emerging. Preclinical and cell-line findings do not reliably predict human outcomes, and where a supplement or drug's evidence base is mostly Level 4–5, we say so explicitly rather than letting a strong mechanism story imply strong human proof.
3. The Five-Layer Cancer Prevention Framework
Think of this as a pyramid. The base is the widest and carries the most human-trial weight; each layer above it is narrower, more specific, and — by the top — restricted to a defined medical population under physician supervision.
| Layer | Source Protocol | Who It's For | Strongest Evidence |
|---|---|---|---|
| 1. Foundation | I-PREVENT | Everyone | ACS/WCRF guidelines, umbrella reviews, RCTs |
| 2. Core Nutraceuticals | ROOT (Root 3) | Everyone, young adults to centenarians | DO-HEALTH RCT, VITAL trial, Minnesota Green Tea Trial |
| 3. Extended Nutraceuticals | ROOT (Root 4-6) + I-PREVENT | Older adults, elevated non-hereditary risk | Mixed RCT/cohort/umbrella review |
| 4. AGE Upgrade | ROOT+ / I-PREVENT | Anyone on Layers 1-3 wanting an add-on | RCT (adenoma recurrence), 22-yr BMJ follow-up |
| 5. Hereditary Rx Tier | ROOT (Root 9) | Confirmed hereditary cancer syndromes only, physician-supervised | Mostly Level 4-5 (preclinical) for ivermectin/mebendazole; celecoxib is FDA-recognized for FAP |
4. Layer 1 — Foundation: Diet, Metabolic Health & Lifestyle
Mammograms, colonoscopies, PSA tests, and CT scans detect disease that has already begun — they don't explain why it started. Layer 1 targets the modifiable, biologically plausible drivers that mainstream prevention messaging tends to under-emphasize.
| Modifiable Driver | Why It Matters |
|---|---|
| Obesity & hyperinsulinemia | Adipose tissue acts as an active endocrine/inflammatory organ, driving insulin resistance, elevated IGF-1, and chronic low-grade inflammation. |
| The Warburg effect | Many tumors are unusually glucose-dependent; chronic hyperglycemia/hyperinsulinemia likely favors a permissive tumor environment. |
| Ultra-processed foods | Linked to inflammation, gut dysbiosis, insulin resistance. See our full ultra-processed food and cancer risk review. |
| Sarcopenia & inactivity | Muscle regulates glucose metabolism and inflammation; loss of muscle mass compounds insulin resistance. |
| Circadian disruption | IARC/WHO classifies shift work with circadian disruption as "probably carcinogenic to humans" (Group 2A). |
| Environmental exposures | Pesticides, microplastics, endocrine disruptors, and air pollution add oxidative and hormonal stress. |
Diet: What the Guidelines and the Newest Data Say
- ACS 2020 guidelines: a healthy eating pattern rich in vegetables, whole fruit, legumes, and whole grains; limits red/processed meat, sugar-sweetened beverages, and refined grains.
- Ultra-processed foods & sugar: a 2026 AACR-published study linked ultra-processed food intake to reduced survival after a cancer diagnosis. A February 2026 Nature Communications study found insulin resistance associated with a 25% higher risk across 12 cancer types (134% higher for uterine cancer). A 2026 BMJ analysis of the French NutriNet-Santé cohort tied food-preservative intake to higher overall and breast cancer rates, independent of age, weight, activity, smoking, and alcohol. A 2024 BMJ umbrella review of 45 pooled analyses (9.88 million participants) linked ultra-processed food to 32 distinct adverse health outcomes, including cancer.
- Mediterranean & plant-forward patterns: a 2024 PLOS One umbrella review of 48 prior reviews found vegetarian/vegan diets "significantly reduce" gastrointestinal-cancer risk; a 2022 meta-analysis of 45 studies found daily olive oil consumers had a 31% lower risk of any cancer. See our Mediterranean diet primer. Cruciferous vegetables (40–60 g/day, roughly half a cup of cooked broccoli) were linked to a 17% lower colon cancer risk in a 2025 analysis of 17 studies (639,539 people).
- Fiber: a 2023 umbrella review (11 meta-analyses) found the strongest fiber intake (25–29 g/day per a 2019 Lancet analysis) associated with lower gastric, esophageal, ovarian, and endometrial cancer risk.
- Meat & cooking methods: IARC classifies processed meat as carcinogenic to humans; charring/high-heat cooking generates heterocyclic amines and PAHs. The red-meat/cancer link itself is less settled — pairing meat with fiber-rich vegetables ("ristoceutics") appears to attenuate risk.
- Fasting, keto, low-carb (controversial): a 2024 Nutrients review found overnight fasting may help but excessive fasting can harm quality of life; a Japanese cohort found low-carb diets raised colorectal/lung cancer risk while lowering gastric cancer risk. Not appropriate if underweight.
- Coffee: a 2021 Nature umbrella review found coffee inversely associated with liver cancer and basal cell carcinoma risk.
Lifestyle
- Tobacco: the single largest modifiable factor — nearly 20% of all cancer cases and close to 30% of cancer deaths.
- Exercise: a landmark 17-year, 880-patient NEJM (2025) randomized trial found a structured 3-year exercise prescription outperformed general activity advice at preventing colon cancer recurrence after high-risk stage 2/3 disease — a result that stunned the ASCO audience it was presented to. A 2025 JNCI analysis found moderate-to-vigorous activity improved survival across 10 cancer types. Strength training meta-analyses show a J-shaped benefit curve, with maximum risk reduction (10–20%) around 30–60 minutes/week and diminishing or reversed benefit above ~140 minutes/week.
- Alcohol: a 2021 Nature umbrella review confirmed alcohol's positive association with postmenopausal breast, colorectal, esophageal, head & neck, and liver cancer risk.
5. Layer 2 — Core Nutraceuticals (Root 3)
Drs. Marik and Hope built the ROOT Protocol as a stepwise, AI-assisted framework that adds one evidence-ranked agent at a time. Root 3 — this layer — is the three-agent foundation Marik and Hope consider a reasonable starting point for essentially everyone, from young adults to centenarians.
| Agent | Key Human Evidence | Primary Mechanism |
|---|---|---|
| Green Tea EGCG | Minnesota Green Tea Trial (RCT, n=1,075): reduced mammographic breast density in postmenopausal women aged 50–55. | Blocks GLUT1/hexokinase-2 (disrupts Warburg effect); shifts tumor-associated macrophages from pro-inflammatory M2 to antitumor M1. |
| Curcumin | 21-study human review (16/21 trials positive); 50+ registered clinical trials, most ongoing. | AKT/mTOR and Wnt/β-catenin inhibition; reduces NF-κB inflammatory signaling; induces apoptosis across many cell lines. |
| Vitamin D3 | DO-HEALTH RCT: adjusted HR 0.39 for invasive cancer in the combined D3+omega-3+exercise arm. VITAL trial: HR 0.72 for cancer mortality. 2025 meta-analysis (50 studies, 1.3M+ participants) linked low D3 to higher colorectal cancer risk. | Stabilizes IκBα (blunts NF-κB); activates Nrf2; upregulates DNA-repair genes (TP53, BRCA1, ATM); inhibits VEGF-driven angiogenesis. |
| Omega-3 (Root 4 add-on) | DO-HEALTH synergy data; CAPFISH-3 RCT (2024): high-omega-3/low-omega-6 diet + fish oil reduced Ki-67 (prostate cancer progression biomarker) over 1 year. | Competes with pro-inflammatory omega-6; activates PPARs; can trigger ferroptosis in acidic tumor microenvironments. |
Practical notes: curcumin needs a bioavailable extract taken with fat or piperine (raw turmeric is only ~3% curcumin by weight with ~1% bioavailability). Target vitamin D3 serum levels of roughly 40–60 ng/mL, pairing with magnesium and vitamin K2 for balance. Use a low-oxidation ("low-TOTOX") omega-3 product — see our omega-3 buying guide (affiliate link; disclosure below). For a bioavailable curcumin option, see this curcumin extract (affiliate link).
6. Layer 3 — Extended Nutraceuticals (Root 4–6 + I-PREVENT)
Root 4 (already covered above via omega-3) is positioned by Marik and Hope as the basic protocol for older adults, since most cancers occur after age 65. Root 5 and Root 6 are for those at elevated but non-hereditary risk. We've merged these with I-PREVENT's own broader supplement list, since the two overlap heavily in both agents and mechanism.
| Agent | Tier | Key Evidence | Mechanism |
|---|---|---|---|
| Berberine | Root 5 | 6-year RCT follow-up (Cell Reports Medicine, 2025): colorectal adenoma recurrence 34.7% vs. 52.1% (placebo) | AMPK activation (metformin-like); BAX↑/BCL2↓; anti-angiogenic via VEGF/MMP inhibition |
| Sulforaphane | Root 6 | Mechanistic + cruciferous-vegetable epidemiology (17% lower colon cancer risk, see Layer 1) | HDAC/DNMT inhibition reactivates silenced tumor-suppressor genes; caspase apoptosis |
| Vitamin C | I-PREVENT | 76-meta-analysis umbrella review: reduced esophageal, gastric, cervical, and lung cancer risk at 50–100 mg/day increments | Antioxidant; whole-food forms retain tyrosinase/copper cofactor activity ascorbic acid lacks |
| Magnesium | I-PREVENT | Swedish Mammography Cohort (61,433 women) and WHI (140,601 women): higher intake linked to lower colorectal cancer risk; Vitamins & Lifestyle cohort: deficiency linked to pancreatic cancer | Cofactor in glucose/insulin signaling regulation |
| Zinc | I-PREVENT | Retrospective studies linking deficiency to hepatocellular carcinoma and Barrett's esophagus progression | Enzymatic/immune cofactor; see our zinc supplementation guide |
| Garlic (dietary) | I-PREVENT | 543,220-participant study: lower stomach cancer risk with high allium intake; 2-5g fresh garlic/day recommended | See Garlic: King of Cancer Prevention |
| Melatonin | I-PREVENT | 2005 systematic review (10 RCTs, n=643 solid-tumor patients): 34% reduced 1-year mortality | Antioxidant; p53↑; anti-angiogenic. See our melatonin guide. Caution in hormone-sensitive cancers. |
| Probiotics / gut microbiome | I-PREVENT | 2018 findings: gut microbes regulate antitumor immune responses in the liver; certain bacteria improve response to anticancer drugs | Gut-liver immune axis modulation |
| Quercetin | I-PREVENT | Phase I trial + preclinical senolytic data | Senolytic, pro-apoptotic. Caution: interacts with anticoagulants, some antibiotics, corticosteroids |
| Carotenoids | I-PREVENT | 2024 umbrella review (51 articles, 198 meta-analyses): dietary intake inversely associated with cancer risk — but high-dose isolated supplements (especially beta-carotene) increased risk | Food-first only; avoid isolated high-dose supplementation |
| Nicotinamide | I-PREVENT | 2025 JAMA Dermatology retrospective (33,822 veterans): decreased risk of 3 skin cancer types | DNA-repair support |
| Beta-glucans | I-PREVENT | Mechanistic + NK-cell activation data (shiitake, maitake, oyster mushrooms) | Complement/dectin-1 receptor activation |
| Molecular Hydrogen | I-PREVENT | 2023 systematic review (27 studies): improved survival as adjuvant. Little evidence for primary prevention specifically. See our molecular hydrogen guide | Selective antioxidant — may blunt ROS-dependent chemo/radiotherapy effects; timing caution during active treatment |
7. Layer 4 — The Aged Garlic Extract (AGE) Upgrade
Aged Garlic Extract is not the same as raw garlic or standard garlic supplements. It's produced through a roughly 20-month aqueous-ethanol aging process that converts unstable compounds like allicin into stable, odorless organosulfur compounds such as S-allyl cysteine. In Marik and Hope's framework, any tier can be upgraded to its "+" variant by adding AGE — and I-PREVENT's own supplement list reaches the same conclusion independently.
- A landmark 2004 RCT (~5,000 participants) found AGE reduced stomach cancer incidence by 52%, strongest in men.
- A 22-year BMJ follow-up (2019) found participants still had 34% lower cancer mortality 17 years after stopping supplementation.
- A separate RCT in colorectal adenoma patients found high-dose AGE over one year significantly reduced adenoma number and size versus low-dose AGE.
Proposed mechanisms include reduced IGF-1, activated autophagy, NF-κB suppression, and up to a 300% boost in Natural Killer cell activity. Standard dosing is 600 mg twice daily. AGE can increase bleeding risk when combined with anticoagulants or antiplatelet drugs. A buying option: Kyolic Aged Garlic Extract Formula 100 (affiliate link).
8. Layer 5 — Hereditary-Risk Prescription Tier (Root 9)
This is where the framework shifts from over-the-counter nutraceuticals to prescription drugs — and where Marik and Hope are explicit that the tier is scoped to a specific population: people with a confirmed inherited cancer syndrome, managed by a physician familiar with hereditary cancer risk. Not the general population. Not a self-directed protocol.
| Syndrome | Gene | Approx. Lifetime Risk |
|---|---|---|
| Hereditary breast/ovarian cancer | BRCA1/BRCA2 | Up to ~70% breast cancer risk in women |
| Li-Fraumeni syndrome | TP53 | >50% risk of multiple cancers |
| Lynch syndrome | Mismatch-repair genes | 50-70% colorectal; up to 60% endometrial (women) |
| Familial adenomatous polyposis (FAP) | APC | Near 100% colorectal cancer without intervention |
Germline mutations of this kind account for roughly 5–10% of all cancers. For carriers, Root 9 layers three additional agents on top of Layers 2–3:
- Celecoxib — a COX-2 inhibitor already FDA-approved as adjunctive therapy for FAP; 400 mg twice daily produced a 28% reduction in colorectal polyps vs. 5% with placebo in trials. This is the one Root 9 component with an established, FDA-recognized dosing regimen for a hereditary-cancer indication.
- Ivermectin — FDA-approved antiparasitic. Preclinical work suggests it may inhibit WNT-TCF signaling (relevant to FAP-associated colorectal cancer), suppress PAK1 kinase (relevant to BRCA-mutated breast cancer models), and induce mitochondrial oxidative stress in pancreatic cancer cell lines — laboratory/animal findings, not confirmed human prevention outcomes.
- Mebendazole — FDA-approved anthelmintic. In the ApcMin/+ mouse model of FAP it reduced intestinal tumor counts by 56% alone, up to 90% combined with sulindac. A phase 2a human trial found doses up to 4 g/day tolerable in advanced GI cancer, though disease progressed in all participants.
Important safety note: Neither ivermectin nor mebendazole has an established human dosing regimen for cancer prevention, and we deliberately do not provide one here. Dosing needs to be individualized by a physician. Dr. Marik himself has reinforced this: in a June 2026 note on our ivermectin/fenbendazole/mebendazole resource page, he specifically flagged a widely circulated high-dose ivermectin cancer protocol as "a potentially toxic dosing protocol which we do NOT recommend." That caution, from one of the therapy's own prominent advocates, deserves serious weight regardless of where you land on the broader debate (see Section 10).
For the complete drug-by-drug mechanistic breakdown of this tier, see the original Vitamin D to Ivermectin: A 2026 Cancer Prevention Framework article.
9. Dosing & Safety Reference Table
| Agent | Layer | Upper Safety Threshold / Range | Key Caution |
|---|---|---|---|
| EGCG (green tea extract) | 2 | Up to ~800 mg/day | Rare hepatotoxicity above 800 mg/day; mild GI upset |
| Curcumin | 2 | Up to ~8 g/day extract | May interact with anticoagulants/antiplatelets; take with fat or piperine |
| Vitamin D3 | 2 | Up to ~5,000 IU/day | Monitor serum calcium; avoid hypercalcemia at high sustained intake |
| Omega-3 (EPA/DHA) | 2 | Bleeding risk rises above ~3 g/day | Use low-TOTOX product; caution with anticoagulants |
| Berberine | 3 | Per product label | Metformin-like effect; caution combining with diabetes medications |
| Melatonin | 3 | 1-2 mg (extended release) at night | Caution in hormone-sensitive cancers (breast, prostate) |
| Quercetin | 3 | Per product label | Interacts with anticoagulants, some antibiotics, corticosteroids, digoxin |
| Aged Garlic Extract | 4 | 600 mg twice daily | Increased bleeding risk with anticoagulants/antiplatelets |
| Celecoxib | 5 | 400 mg twice daily (FAP-specific, FDA-recognized) | Physician-prescribed only; cardiovascular/GI risk profile of COX-2 inhibitors applies |
| Ivermectin | 5 | No established cancer-prevention dose — not provided here | Physician-supervised, hereditary-syndrome context only; avoid unsupervised high-dose protocols |
| Mebendazole | 5 | No established cancer-prevention dose — not provided here | Physician-supervised, hereditary-syndrome context only |
Reported adverse events across the Layer 2 core agents combined were mostly mild in the underlying trial data: gastrointestinal symptoms (~15%), headache (~5%), and fatigue (~3%). Anyone pregnant, immunocompromised, or on anticoagulant therapy should check with a physician before starting any layer above the diet/lifestyle foundation.
10. The 2026 Evidence Debate: ASCO vs. the Repurposed-Drug Camp
Any honest discussion of Layer 5 has to include where organized oncology currently stands. In a Clinical Notice published in June 2026, the American Society of Clinical Oncology stated there is no robust, peer-reviewed clinical evidence that either ivermectin or fenbendazole is safe or effective for treating any human malignancy, and cautioned that both should stay within the regulatory safeguards of a formal clinical trial rather than being used as a cancer treatment or adjunct outside one. ASCO's Chief Medical Officer specifically flagged social-media and podcast-driven misinformation as a safety concern, while acknowledging legitimate human trials remain in early stages — including a phase I/II ivermectin-plus-checkpoint-inhibitor study in metastatic triple-negative breast cancer, and the phase II ICONIC trial expected to begin enrolling in July 2026.
Dr. Marik has pushed back on that framing, arguing that demanding large randomized trials before considering low-cost, off-patent therapies sets a bar that mainly well-funded pharmaceutical products can clear, and that carefully tracked observational cohorts can still generate meaningful signal while formal trials catch up.
We think both points are worth holding onto at once. ASCO's underlying factual claim — that no large, peer-reviewed human trial currently demonstrates ivermectin or fenbendazole benefit in cancer — is accurate as of this writing, and the toxicity concern is real: unsupervised, high-dose regimens circulating online use doses well above those approved for parasitic infections. At the same time, Layer 5 as defined here already narrows its drug component to a specific, physician-supervised, hereditary-risk population — a meaningfully different (and more conservative) proposal than the general "take ivermectin for cancer" claims ASCO's notice addresses. Treat Layer 5 as an open scientific question to raise with an oncologist or integrative oncologist, not a settled, self-directed regimen.
11. Which Layers Are Right for You?
| Your Situation | Suggested Layers |
|---|---|
| Generally healthy, no known risk factors | Layer 1 + Layer 2 |
| Age 65+ | Layers 1-2, consider adding Layer 3 agents |
| Elevated but non-hereditary risk (family history without a confirmed mutation, prior polyps, metabolic syndrome) | Layers 1-3, discuss Layer 4 with your physician |
| Confirmed hereditary cancer syndrome (BRCA1/2, Lynch, FAP, Li-Fraumeni) under specialist care | Layers 1-4; discuss Layer 5 explicitly with a physician experienced in hereditary cancer risk |
| Currently in active cancer treatment or a survivor | This is a prevention framework, not a treatment protocol. Coordinate any of the above with your oncology team, and consult our treatment-focused resources (e.g., our ivermectin for cancer treatment and related case-series articles) separately. |
12. Key Takeaways
- Cancer prevention in 2026 is increasingly framed around metabolic health, chronic inflammation, and environmental exposure — not genetics alone.
- Layer 1 (diet, weight, exercise, tobacco/alcohol avoidance) carries the broadest and strongest human evidence of any layer in this framework, including a landmark NEJM trial showing structured exercise outperforming general advice at preventing colon cancer recurrence.
- Layer 2 (EGCG, curcumin, vitamin D3, omega-3) is anchored by the DO-HEALTH and VITAL randomized trials — the strongest human-trial support of any nutraceutical tier.
- Layers 3-4 add a wider set of agents with plausible mechanisms and growing, but not always definitive, human data.
- Layer 5 (celecoxib, ivermectin, mebendazole) is explicitly designed for people with confirmed hereditary cancer syndromes under specialist supervision — not a general-population or self-directed protocol.
- ASCO's 2026 Clinical Notice and Dr. Marik's own caution about high-dose ivermectin protocols both deserve serious weight; this is an active, unresolved evidence debate, not a settled question.
- This framework is for cancer prevention in healthy or at-risk adults — it is not a substitute for oncology care in anyone already diagnosed.
13. Frequently Asked Questions
What is the difference between I-PREVENT and the ROOT Protocol?
I-PREVENT is OneDayMD's own diet-lifestyle-and-broad-supplement framework, running since 2022. ROOT is Dr. Paul Marik and Dr. Justus Hope's sequential nutraceutical-to-prescription-drug escalation ladder. This article merges both into one five-layer system so readers don't have to reconcile two separate frameworks themselves.
What is the ROOT Protocol for cancer prevention?
A tiered framework starting with EGCG, curcumin, and vitamin D3 (Root 3), adding omega-3, berberine, and sulforaphane through Root 6, and finally adding celecoxib, ivermectin, and mebendazole at Root 9 for people with hereditary cancer syndromes.
Is this framework scientifically proven to prevent cancer?
Individual components have trial or preclinical support of varying strength; the combined framework itself hasn't been tested as a single protocol in a large randomized trial, and Layer 5's drug component remains investigational.
Who should consider Layer 5 (Root 9)?
Only people with a confirmed hereditary cancer syndrome (e.g., BRCA1/2, Lynch syndrome, FAP), working with a physician experienced in hereditary cancer risk.
What does ASCO say about ivermectin and fenbendazole?
Its June 2026 Clinical Notice states there is no robust, peer-reviewed clinical evidence supporting either drug for treating human cancer, and recommends against use outside a clinical trial.
Can I use this framework if I already have cancer?
This is a prevention framework for healthy or at-risk adults, not a treatment protocol. If you're in active treatment or are a survivor, discuss any of these layers with your oncology team first.
What's the single highest-priority layer for most people?
Layer 1. Diet, weight management, exercise, and avoiding tobacco/excess alcohol have the largest, most consistent body of human evidence of any layer in this framework.
14. Medical Disclaimer & Disclosures
Evidence grading: Throughout this article we distinguish randomized controlled trial data (DO-HEALTH, VITAL, the berberine adenoma-recurrence trial, the AGE trials) from preclinical/mechanistic evidence (most of the ivermectin and mebendazole data) and from single observational cohorts. Preclinical and cell-line findings do not reliably predict human outcomes.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Nothing here should be used to start, stop, or replace any cancer treatment or screening plan. Decisions about supplements or off-label/repurposed drug use — especially celecoxib, ivermectin, and mebendazole — should be made with a qualified physician familiar with your medical history, current treatments, and, where relevant, your genetic risk profile.
Conflict of interest disclosure: OneDayMD maintains affiliate relationships with The Wellness Company (referral code ONEDAYMD). Some product links on this site are affiliate links, meaning we may earn a commission at no additional cost to you. This did not influence the content, evidence grading, or safety cautions presented above. We have no financial relationship with Dr. Marik, Dr. Hope, or the Independent Medical Alliance.
Related Reading
- I-PREVENT Cancer Protocol (original)
- Vitamin D to Ivermectin — A 2026 Cancer Prevention Framework (ROOT, original)
- Ivermectin, Fenbendazole and Mebendazole: A Peer-Reviewed Protocol Review
- Dr. Paul Marik's Cancer Care, 2nd Edition: Full Review
- How Ultra-Processed Foods Wreck Your Health
- Mediterranean Diet 101
.png)
.png)
Comments
Post a Comment